search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
COVID-19 Expect the unexpected


Helén Johansen Blanco, head of clinical operations at Oncoinvent, discusses risk management versus issues management when dealing with the unexpected.


Islandic volcano Eyjaf allajökulls erupted in 2010, and fl ight transports and delivery of drugs to a site was aff ected to a high extent, which led to a focus on proactive risk assessment. What is truly unexpected? Could we have anticipated the Covid-19 pandemic somehow or could we, at the very least, have foreseen the consequences? Many companies off ered support and solutions on how to deal with the pandemic consequences. The best and most realistic to implement was received exactly fi ve weeks after hospitals had opened up for recruitment to clinical trials and external visitors. This then raises the following question: when does a risk turn into an issue? And how is the transfer adequately managed? This article will attempt to answer


T


he Covid-19 pandemic has highlighted the need for knowledge when dealing with the unexpected. Many will recall when the


a few of these questions; the purpose is not to provide answers in full, but to create a debate in order to improve the management of risks and issues in the long run.


Mitigate risk before it becomes an issue Literature within the fi eld of project management describes that the most successful projects are those where the team was acting in a proactive manner. Although this is often set by the leadership style of the project manager, everyone can adapt to a proactive way of working by establishing robust processes for risk management. Having a standard operating procedure in place for risk and issue management; describing frequency of risk assessment; cross-functional involvement; assessment of risk score by rating impact and likelihood; and following up of proactive actions to reduce risk – either by impact and/or likelihood


80 | Outsourcing in Clinical Trials Handbook


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120